Abstract：The Budd-Chiari syndrome (BCS) used to be a very rare disorder and lacked a means of relieving. However, various shuntings and radical procedures have emerged in the last three decades with quite encouraging outcomes. Recent minimally invasive therapies, such as stenting of the inferior vena cava (IVC), are simple and easy to handle. However, it has been realized that the IVC stent may compromise the hepatic veins and cause catastrophic consequences, thus the indication for IVC stenting should be reevaluated and especially not to be overused. Instead, it should be applied by percutaneous transangiography (PTA) only, which may be repeated when necessary. The BCS in China predominantly belongs to the IVC type rather than the intrahepatic type in Western; the outcome from its conventional therapy, at least for the moment, is better than that of liver transplantation. It is thus suggested that, before liver transplantation is decided, the conventional means for managing BCS be considered. The final suggestion is to restrict the indication both for stenting of the IVC and liver transplantation. In this paper, ten examples are given with figures.
出版日期: 2007-06-05
引用本文:
. To restrict indication for stenting of the inferior vena cava and liver transplantation in patients with Budd-Chiari syndrome[J]. Frontiers of Medicine in China, 2007, 1(2): 130-135.
WANG Zhonggao. To restrict indication for stenting of the inferior vena cava and liver transplantation in patients with Budd-Chiari syndrome. Front. Med., 2007, 1(2): 130-135.
